A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO
Shares of cancer drug startup, whose investors include Carlyle Group and Temasek, are down 7% a week after their trading debut Key takeaways Four rounds of fundraising together with IPO…
Recent Articles
RELATED ARTICLES
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG -
Akeso marks profit milestone with swift rights issue
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- InSilico seeks IPO boost to get AI drugs over the line
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
